This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fries, L F Articles by Williams, J C Search for Related Content PubMed PubMed Citation Articles by Fries, L F Articles by Williams, J C

Safety and immunogenicity in human volunteers of a chloroform-methanol residue vaccine for Q fever.

Department of International Health, Johns Hopkins University School of Hygiene and Public Health, Baltimore, Maryland 21205.

ABSTRACT

Current Q fever vaccines, consisting of Formalin-inactivated phase I whole Coxiella burnetii, are highly efficacious in preventing disease in high-risk settings but are associated with a risk of unacceptable local reactions in previously immune individuals and require cumbersome preliminary immunologic evaluation of potential vaccinees. A vaccine prepared from the residue of chloroform-methanol extraction of phase I Henzerling strain C. burnetii (CMR) has been shown to be less reactogenic but still immunogenic and protective in small animals and sheep. In a placebo-controlled trial, we immunized 35 healthy adults unscreened for markers of prior C. burnetii immunity with a single subcutaneous CMR dose of 30, 60, 120, or 240 micrograms. None of those receiving the 30- or 60-micrograms CMR dose and none of the placebo recipients experienced any adverse effects. Five of 15 120-micrograms dose CMR recipients complained of transient discomfort in the inoculated arm; erythema or induration of > or = 100 mm2 was noted in three and four, respectively, and two had malaise and low-grade fever (< 101 degrees F, orally). No 240-micrograms dose vaccinee reported limb discomfort, but 7 of 10 had erythema and/or induration of > or = 100 mm2 (P < 0.001 versus placebo). Two reported malaise, and one had low-grade fever. All adverse effects were self-limited. Serum immunoglobulin M responses were optimally detected with CMR antigen and occurred in 50, 60, 73, and 90% of recipients of the 30-, 60-, 120-, and 240-micrograms doses, respectively; results with phase I whole-cell antigen were similar. Serum immunoglobulin G responses were best detected with phase II antigen and were seen in 20, 20, and 40% of those receiving the 60-, 120-, and 240-micrograms doses, respectively. Peripheral blood T-cell proliferative responses to C. burnetii recall antigens were transient and of low magnitude but were seen with CMR antigen in 33% of 120-micrograms dose recipients and 40% of 240-micrograms dose recipients. Data from this study and those from comparative-efficacy trials in primates should provide the basis for field trials of the CMR vaccine.

This article has been cited by other articles:

• KAZAR, J. (2005). Coxiella burnetii Infection. Ann. N. Y. Acad. Sci. 1063: 105-114 [Abstract] [Full Text]  
• LI, Q., NIU, D., WEN, B., CHEN, M., QIU, L., ZHANG, J. (2005). Protective Immunity against Q Fever Induced with a Recombinant P1 Antigen Fused with HspB of Coxiella burnetii. Ann. N. Y. Acad. Sci. 1063: 130-142 [Abstract] [Full Text]  
• TYCZKA, J., EBERLING, S., BALJER, G. (2005). Immunization Experiments with Recombinant Coxiella burnetii Proteins in a Murine Infection Model. Ann. N. Y. Acad. Sci. 1063: 143-148 [Abstract] [Full Text]  
• Maurin, M., Raoult, D. (1999). Q Fever. Clin. Microbiol. Rev. 12: 518-553 [Abstract] [Full Text]